0
0
41 words
0
Comments
Study shows statistically significant survival gain – 16.2 months versus 14.16 – in what Novocure says is the first new treatment in decades for locally advanced pancreatic cancer
You are the first to view
https://www.haaretz.com/science-and-health/2026-02-18/ty-article/fda-approves-pancreatic-cancer-device-that-extends-survival-from-israeli-founded-novocure/0000019c-7016-d631-a3de-7d9ea8560000
Create an account
or login to join the discussion